<?xml version="1.0" encoding="UTF-8"?>
<p>In the 1980s, cases of biochemical abnormalities, including hyperosmolarity, lactic acidosis and elevated levels of creatinine and bilirubin, were documented after exposure to 3 g/day of PG and for at least 5 consecutive days. Clinical symptoms, including seizures and bradycardia episodes [
 <xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>], then appeared. In 2011, the U.S. FDA reported health problems in premature new-borns associated with the use of Kaletra
 <sup>Â®</sup> (lopinavir/ritonavir) solution; liquid preparation containing high amounts of PG and ethanol [
 <xref rid="B33-pharmaceutics-13-00387" ref-type="bibr">33</xref>,
 <xref rid="B34-pharmaceutics-13-00387" ref-type="bibr">34</xref>].
</p>
